title: Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
abstract: OBJECTIVE
  The aim of this study was to describe the clinicopathologic features and prognosis of endometrial cancer patients diagnosed during or after tamoxifen treatment for breast cancer.
  
  
  METHODS
  Fifty-six tamoxifen-related endometrial cancers were identified from 10 hospitals in Japan. Past users were defined as endometrial cancer patients diagnosed more than 12 months after the cessation of tamoxifen treatment for breast cancer. All other users were classified as recent users.
  
  
  RESULTS
  Age at diagnosis of the endometrial cancer ranged from 29 to 81 years. Sixteen (29%) and 19 (34%) patients were nulliparous and overweight, respectively. When the patients were divided into two groups: 30 recent and 26 past users, the distribution of various clinical characteristics, except for age at the time of diagnosis for endometrial cancer and the interval between the diagnoses of two cancers, was similar for two groups. The daily dose, duration and cumulative dose also showed no significant difference between the two groups. Past users had histopathologically more invasive tumors showing prognostically more unfavorable subtypes than recent users. The background lesions including endometrial polyps and diffuse cystic changes were similar for the two groups. The cumulative 3-year survival was significantly worse for past users than for recent users (74.8% and 96.4%, respectively, P < 0.04). In multivariate analysis including recentness of tamoxifen use and age at diagnosis of endometrial cancer, the significance of past user disappeared.
  
  
  CONCLUSIONS
  Past users had a worse prognosis of endometrial cancer with more invasive histologic features than recent users, probably because they included more elderly patients.
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University School of Medicine, 45-1, 7-chome, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. hachisug@fukuoka-u.ac.jp
authors.forename: Toru
authors.initials: T
authors.lastname: Hachisuga
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Saito
authors.forename: Junzo
authors.initials: J
authors.lastname: Kigawa
authors.forename: Michitaka
authors.initials: M
authors.lastname: Ohwada
authors.forename: Koji
authors.initials: K
authors.lastname: Yamazawa
authors.forename: Akira
authors.initials: A
authors.lastname: Yasue
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Iwasaka
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Kita
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Nagai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D013629:Tamoxifen